<?xml version="1.0" ?><!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st June 2018//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_180601.dtd"><PubmedArticleSet><PubmedArticle>    <MedlineCitation Status="Publisher" Owner="NLM">        <PMID Version="1">30415009</PMID>        <DateRevised>            <Year>2018</Year>            <Month>11</Month>            <Day>11</Day>        </DateRevised>        <Article PubModel="Print-Electronic">            <Journal>                <ISSN IssnType="Electronic">1879-0038</ISSN>                <JournalIssue CitedMedium="Internet">                    <PubDate>                        <Year>2018</Year>                        <Month>Nov</Month>                        <Day>08</Day>                    </PubDate>                </JournalIssue>                <Title>Gene</Title>                <ISOAbbreviation>Gene</ISOAbbreviation>            </Journal>            <ArticleTitle>Expression and prognosis analyses of forkhead box A (FOXA) family in human lung cancer.</ArticleTitle>            <ELocationID EIdType="pii" ValidYN="Y">S0378-1119(18)31165-X</ELocationID>            <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.gene.2018.11.022</ELocationID>            <Abstract>                <AbstractText>Despite advances in early diagnosis and treatment, cancer still remains the major reason of mortality worldwide. The forkhead box A (FOXA) family is reported to participate in diverse human diseases. However, little is known about their expression and prognostic values in human lung cancer. Herein, we conducted a detailed cancer vs. normal analysis. The mRNA expression levels of FOXA family in numerous kind of cancers, including lung cancer, were analyzed using the Oncomine and GEPIA database. We observed that the mRNA expression levels of FOXA1, and FOXA3 were all increased while FOXA2 were decreased in most cancers compared with normal tissues, especially in lung cancer. Moreover, the expression levels of FOXA1, and FOXA3 are also highly expressed, while FOXA2 were decreased in almost all cancer cell lines, particularly in lung cancer cell lines, analyzing by Cancer Cell Line Encyclopedia (CCLE) and EMBL-EBI databases. Furthermore, the LinkedOmics database was used to evaluate the prognostic values, indicating that higher expression of FOXA1, FOXA3 indicated a poor overall survival (OS), while increased FOXA2 revealed a better OS in lung cancer. To conclusion, FOXA family showed significant expression differences between cancer and normal tissues, especially lung cancer, and FOXA1, FOXA3 could be promising prognostic biomarkers for lung cancer.</AbstractText>                <CopyrightInformation>Copyright Â© 2018. Published by Elsevier B.V.</CopyrightInformation>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Huang</LastName>                    <ForeName>Chaoqun</ForeName>                    <Initials>C</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Gastrointestinal Surgery, Zhongnan Hospital of Wuhan University, PR China; Hubei Key Laboratory of Tumor Biological Behaviors &amp; Hubei Cancer Clinical Study Center, 430071 Wuhan, Hubei, PR China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Liu</LastName>                    <ForeName>Jiuyang</ForeName>                    <Initials>J</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Thyroid and Breast Surgery, Zhongnan Hospital of Wuhan University, PR China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Xiong</LastName>                    <ForeName>Bin</ForeName>                    <Initials>B</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Gastrointestinal Surgery, Zhongnan Hospital of Wuhan University, PR China; Hubei Key Laboratory of Tumor Biological Behaviors &amp; Hubei Cancer Clinical Study Center, 430071 Wuhan, Hubei, PR China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Yonemura</LastName>                    <ForeName>Yutaka</ForeName>                    <Initials>Y</Initials>                    <AffiliationInfo>                        <Affiliation>Peritoneal Dissemination Center, Kishiwada Tokushukai Hospital, Kishiwada 596-0032, Japan; Department of Surgery, Kusatsu General Hospital, Shiga 600-8189, Japan.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Yang</LastName>                    <ForeName>Xiaojun</ForeName>                    <Initials>X</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Gastrointestinal Surgery, Zhongnan Hospital of Wuhan University, PR China; Hubei Key Laboratory of Tumor Biological Behaviors &amp; Hubei Cancer Clinical Study Center, 430071 Wuhan, Hubei, PR China. Electronic address: totti800105@163.com.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>            </PublicationTypeList>            <ArticleDate DateType="Electronic">                <Year>2018</Year>                <Month>11</Month>                <Day>08</Day>            </ArticleDate>        </Article>        <MedlineJournalInfo>            <Country>Netherlands</Country>            <MedlineTA>Gene</MedlineTA>            <NlmUniqueID>7706761</NlmUniqueID>            <ISSNLinking>0378-1119</ISSNLinking>        </MedlineJournalInfo>        <KeywordList Owner="NOTNLM">            <Keyword MajorTopicYN="N">Cancer cell line encyclopedia</Keyword>            <Keyword MajorTopicYN="N">Forkhead box A</Keyword>            <Keyword MajorTopicYN="N">Lung cancer</Keyword>            <Keyword MajorTopicYN="N">Oncomine</Keyword>        </KeywordList>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="received">                <Year>2018</Year>                <Month>08</Month>                <Day>07</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="revised">                <Year>2018</Year>                <Month>11</Month>                <Day>04</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="accepted">                <Year>2018</Year>                <Month>11</Month>                <Day>08</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>11</Month>                <Day>12</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>11</Month>                <Day>12</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>11</Month>                <Day>12</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>aheadofprint</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30415009</ArticleId>            <ArticleId IdType="pii">S0378-1119(18)31165-X</ArticleId>            <ArticleId IdType="doi">10.1016/j.gene.2018.11.022</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle></PubmedArticleSet>